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Zika vaccines and therapeutics: landscape
analysis and challenges ahead
Annelies Wilder-Smith1,2,3*, Kirsten Vannice1, Anna Durbin4, Joachim Hombach1, Stephen J. Thomas5,
Irani Thevarjan6,7 and Cameron P. Simmons8,9
Abstract
Background: Various Zika virus (ZIKV) vaccine candidates are currently in development. Nevertheless, unique
challenges in clinical development and regulatory pathways may hinder the licensure of high-quality, safe, and
effective ZIKV vaccines.
Discussion: Implementing phase 3 efficacy trials will be difficult given the challenges of the spatio-temporal
heterogeneity of ZIKV transmission, the unpredictability of ZIKV epidemics, the broad spectrum of clinical manifestations
making a single definite endpoint difficult, a lack of sensitive and specific diagnostic assays, and the need for inclusion
of vulnerable target populations. In addition to a vaccine, drugs for primary prophylaxis, post-exposure prophylaxis, or
treatment should also be developed to prevent or mitigate the severity of congenital Zika syndrome.
Conclusion: Establishing the feasibility of immune correlates and/or surrogates are a priority. Given the challenges in
conducting phase 3 trials at a time of waning incidence, human challenge trials should be considered to evaluate
efficacy. Continued financial support and engagement of industry partners will be essential to the successful
development, licensure, and accessibility of Zika vaccines or therapeutics.
Keywords: Zika, Zika vaccines, Flavivirus, Anti-virals, Prophylaxis, Therapeutics, Efficacy trials, Zika diagnostics,
Monoclonal antibodies, Immune correlates, Immune surrogates, Human controlled infections, Clinical endpoints
Background
The devastating consequences of Zika virus (ZIKV) in-
fection, leading to congenital Zika syndrome (CZS) and
neurological complications such as Guillain–Barre Syn-
drome (GBS), led the World Health Organization
(WHO) to declare a Public Health Emergency of Inter-
national Concern on February 1, 2016 [1], and to call on
the global research and product development (R&D)
communities to prioritize the development of preventa-
tive and therapeutic solutions [2]. The R&D communi-
ties responded rapidly, with 45 vaccine candidates being
initially evaluated in non-clinical studies and most pro-
gressing to active development. Of these, several have
advanced beyond pre-clinical studies in animals and en-
tered phase 1 human trials [3, 4], with two candidates
having entered phase 2 trials (https://clinicaltrials.gov/
ct2/show/NCT03110770, https://clinicaltrials.gov/ct2/
show/NCT03014089). Additionally, the role of thera-
peutic and prophylactic medicinal products in the man-
agement of ZIKV infections in pregnant women and
other high-risk groups remains to be determined.
Herein, we describe the various vaccine platforms, with
a discussion on their advantages and disadvantages in
the context of use scenarios, and provide an overview of
the current status of vaccine development. Furthermore,
we propose three plausible clinical indications for
prophylactic or therapeutic agents against ZIKV. Both
vaccines and therapeutics must be evaluated for their
efficacy in human trials, yet the design of efficacy trials
and the appropriate selection of clinical endpoints pose
a challenge. In particular, the rapid decline in Zika cases
in the second year following the Public Health
Emergency of International Concern declaration has put
clinical efficacy trial feasibility at stake. We discuss op-
tions on how best to address these hurdles.
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ZIKV vaccines
WHO has outlined two use scenarios for a ZIKV vaccine
[5], namely in emergency outbreak response and for en-
demic transmission. Emergency outbreak response involves
a targeted mass vaccination during an ongoing epidemic or
an imminent outbreak of ZIKV to prevent ZIKV-associated
disease in women of child-bearing age in order to mitigate
CZS. Endemic transmission use involves a broad or univer-
sal vaccination campaign of the general population in the
inter-epidemic period, extending from early childhood to
adults, followed by routine immunization, in order to estab-
lish population immunity to prevent transmission, and ul-
timately to prevent ZIKV-related adverse birth outcomes
and neurological complications.
Based on current knowledge on the transmission of
ZIKV and experiences with past disease outbreaks,
WHO has prioritized the development of vaccines suit-
able for use in an emergency or outbreak scenario.
Therefore, and in line with the WHO Zika Strategic
Response plan, WHO developed a Target Product Profile
for a ZIKV vaccine for emergency use where
immunization of women of reproductive age is consid-
ered to be of highest priority [5]. Although WHO de-
clared an end to its global health emergency over the
spread of ZIKV on November 18, 2016, the long-term
need for a ZIKV vaccine continues [6]. Under the Blue-
print Plan of Action [7].
WHO led a series of initiatives to maintain continuous
dialogue between developers, regulators, and public
health experts to identify how best to achieve rapid, ro-
bust, safe, and evidence-based licensing of ZIKV vac-
cines. In June 2016, WHO hosted an expert consultation
on regulatory considerations for ZIKV vaccine develop-
ment, outlining vaccine platform focal points for devel-
opers and regulators, as well as the mechanisms of
approval [8]. In June 2017, additional information was
provided regarding clinical trial endpoints and trial site
selection. WHO has also hosted periodic meetings to re-
view the progress of ZIKV vaccine development and fos-
ter opportunities for data sharing [9, 10].
Factors that render the development of a ZIKV vaccine
feasible
Although ZIKV strains are categorized into two genetic
lineages, African and Asian/American, ZIKV has been
classified as a single serotype with limited strain variabil-
ity [11]. Recent studies on macaques showed that im-
mune responses primed by infection with East African
ZIKV completely protected macaques from detectable
viremia when subsequently re-challenged with heterol-
ogous Asian ZIKV [12]; thus, a ZIKV vaccine based on a
single ZIKV strain may be sufficient. Successful vaccines
have been developed for other single serotype flavi-
viruses such as yellow fever, Japanese encephalitis (JEV),
and tick-borne encephalitis (TBEV), with well-defined
correlates of protection, thus rendering the development
of a monovalent vaccine against ZIKV with a favorable
probability of technical and regulatory success [8]. Early
findings from animal studies suggest a protective thresh-
old of ZIKV vaccine-induced neutralizing activity that
prevents viremia after acute infection, as determined
after challenge with an infective dose [13, 14]. Three dif-
ferent vaccine platforms have been tested in non-human
primate models, with all showing 100% protection
against viremia following a ZIKV challenge [15, 16].
Additionally, various vaccine platforms have been tested
for their ability to protect against ZIKV transmission to
the fetus [17], with the findings showing markedly di-
minished levels of viral ZIKV RNA in maternal, placen-
tal, and fetal tissues, which resulted in protection against
placental damage and fetal demise [17]. These studies
are therefore a proof-of-concept that protection against
CZS is possible.
Potential hurdles to ZIKV vaccine development
Several important hurdles may impede ZIKV vaccine de-
velopment. Firstly, given the early stages of development
of animal models for ZIKV infection, disease, maternal–
fetal transmission, and fetal infection, their relevance to
the human experience requires additional validation.
Current evidence suggests that even asymptomatic infec-
tions with presumably low levels of viremia in the
mother could result in CZS [18]. It is unknown whether
sterilizing immunity and robust T cell response are re-
quired to avert transplacental transmission of ZIKV dur-
ing pregnancy [19]. Answering these questions will be
critical for the development of a vaccine that protects
against CZS. If sterilizing immunity is indeed required,
this would set a high bar for a ZIKV vaccine since, simi-
lar to other flavivirus vaccines (e.g., JEV, dengue viruses
(DENV), and TBEV), sterilizing immunity has not yet
been achieved. Optimally, the efficacy afforded by a
ZIKV vaccine would be durable, as protection through-
out the reproductive years is desired.
Secondly, concerns have been raised about the hypo-
thetical risk of vaccine-associated GBS given the associ-
ation of natural ZIKV infection with a higher risk of
GBS [20, 21]. If the mechanism of ZIKV-associated GBS
is direct neuroinvasion, there could be implications for
the design of neurovirulence testing of live attenuated
ZIKV vaccines [8]. Conversely, if GBS is immune medi-
ated, there could be implications for all ZIKV vaccines.
The sequence and antigenic similarity between ZIKV
and DENV [22], and potentially also other flaviviruses,
has led some to speculate whether pre-existing immun-
ity to one or more flaviviruses could impact clinical out-
comes following a subsequent ZIKV infection, as many
of these flaviviruses co-circulate [23, 24]. Whilst in vitro
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studies have generated evidence in support of immune
enhancement [23] between DENV and ZIKV, an increas-
ing body of evidence from in vivo non-human primate
studies [25, 26] and observational studies in humans
[27] have shown a lack of association between more se-
vere ZIKV disease and prior DENV infections, which is
reassuring for vaccine development. Nevertheless, care-
ful monitoring will be needed, and clinical trial study de-
signs should ideally include evaluation of safety and
immunogenicity, as well as of the potential for clinical
benefit in both flavivirus-primed and naive populations.
Current ZIKV vaccine platforms
Both traditional (purified inactivated, live attenuated,
recombinant sub-unit) and more novel (DNA, self-
replicating RNA, messenger RNA (mRNA), viral-
vectored) ZIKV vaccine platforms are in development.
In July 2016, WHO developed a catalog of preclinical
and clinical ZIKV vaccines by searching the WHO Inter-
national Clinical Trial Registry Platform [28] and the
National Institutes of Health (NIH) clinical trial registry
(ClinicalTrials.gov), by literature review, and by contact-
ing research groups in academia and industry. Table 1
highlights the ZIKV vaccine candidates in clinical devel-
opment as of October 2017, and Table 2 outlines ZIKV
vaccine candidates in the preclinical phase as of January
2017. Additionally, WHO maintains an updated list of
ZIKV vaccine clinical trials through the WHO clinical tri-
als tracker [29]. Below, we discuss the potential advantages
and disadvantages of the various platforms, and highlight
selected vaccines that have entered clinical trials.
Nucleic acid vaccines
Nucleic acid vaccines have advanced the furthest in
clinical development. Both DNA plasmid-based vac-
cines and mRNA vaccines have utility due to their
ease of production since encoding genes can easily be
replaced [30], and thus have potential for scalability
during an outbreak. They exhibit characteristics of
subunit vaccines and live attenuated vectors, with
conceptual safety advantages [22]. However, to date,
neither a DNA nor an mRNA vaccine candidate has
been evaluated in a phase 3 trial nor licensed for use
in the prevention of another flavivirus infection, un-
like live, vectored, and inactivated vaccine platforms.
A limitation of DNA plasmid vaccines is the delivery
technology needed for optimal protein production.
For example, electroporation, i.e., the use of a pulsed
electric field to introduce the DNA sequence into
cells [30], would make large scale deployment in low-
resource settings more difficult. A potential concern
with DNA vaccines is that there might be a small
possibility of chromosomal integration by non-
homologous recombination, which may lead to cell
transformation by insertional mutagenesis [31]. Con-
versely, mRNA molecule-based vaccines act in the
cytoplasm and thus do not pose a risk of chromo-
somal integration.
DNA ZIKV vaccines
Inovio Pharmaceuticals and GeneOne Life Science,
Inc. (KSE: 011000) have developed a synthetic, con-
sensus DNA vaccine (GLS-5700) encoding the ZIKV
premembrane (prM) and envelope (E) proteins, ad-
ministered with the CELLECTRA®-3P device, Inovio’s
proprietary intradermal DNA delivery device. The
delivery technology is based on electroporation. The
interim analysis of the phase 1, open-label clinical
trial at 14 weeks (i.e., after the third dose of vaccine
given in a 0–4 and 14 weeks schedule) evaluated the
safety and immunogenicity of GLS-5700 in two
groups of 20 participants each (NCT02809443) [32].
No serious adverse events were reported. After the
third vaccine dose, binding antibodies (as measured
on enzyme-linked immunosorbent assay) were
detected in all participants. Neutralizing antibodies
developed in 62% of the vaccine recipients on the
Vero-cell assay. On a neuronal-cell assay, there was
90% inhibition of ZIKV infection in the serum sam-
ples of 70% of vaccine recipients and 50% inhibition
in 95% of vaccine recipients. Further, the intraperito-
neal injection of post-vaccination serum protected
103 of 112 (92%) IFNAR knockout mice that were
challenged with a lethal dose of ZIKV-PR209 strain.
The US NIH Vaccine Research Center is advancing
a ZIKV DNA vaccine candidate based on the technol-
ogy it developed for a highly immunogenic West Nile
virus DNA vaccine [33], whereby the full coding se-
quences of the prM and E genes of ZIKV are inserted
into their DNA construct. In this manner, virus-like
subviral particles are released after expression of prM
and E [13]. The National Institute of Allergy and In-
fectious Diseases (NIAID) is using a needleless
pressure-based delivery system developed by the com-
pany PharmaJet, with results from immunogenicity
and protective efficacy studies in mice and in rhesus
monkeys indicating high levels of protection [13]. The
phase 1 clinical trial of this DNA vaccine started in
September 2016 and a phase 2a clinical trial in Texas
and Puerto Rico was initiated in April 2017 [34]. A
phase 2b trial is scheduled to begin before the end of
2017 in multiple sites with the potential for ZIKV
transmission [35].
mRNA vaccines
Modified ZIKV prM-E mRNA molecules were encapsu-
lated in lipid nanoparticles in vaccine formulations [36, 37],
showing complete protection in animal studies against
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Table 2 WHO – Pipeline Zika virus (ZIKV) vaccines (in preclinical development) (last updated January 2017) January 2017)
Platform Candidate
vaccine name
Developer/Collaborators Replicating virus
(Yes/No)
Antigen Adjuvant
Inactivated whole
target organism
BK1603 BIKEN No ZIKV full genome To be determined
Inactivated whole
target organism
Bio-Manguinhos in house
development and Sanofi
Pasteur/WRAIR
(discontinued in 2017)
No ZIKV full genome Alum
Recombinant
subunit (non- VLP)
Bio-Manguinhos
partnership
No ZIKV E protein Alum
Recombinant
viral vector
Bio-Manguinhos/Aggeu
Magalhaes (FIOCRUZ)
Yes PrM/E and PrM/E/NS1 None
Live, attenuated
recombinant virus
Brazilian Ministry of Health
agreement with University
of Texas
Yes rZIKV None
rZIKV NS1
Inactivated whole
target organism
Butantan ZIKV Butantan No ZIKV full genome Alum
Live, attenuated
target organism
Butantan
attenuated ZIKV
Butantan ZIKV full genome None
Inactivated virus +
aluminum adjuvant
ZIKV Emergent BioSolutions No ZIKV full genome Aluminum
Recombinant
viral vector
GEO-ZM05 GeoVax/University of
Georgia/CDC Atlanta, US
No ZIKV PrM/E + NS1 None
SAM WT GSK-NIH Yes ZIKV prM/E
SAM CO GSK-NIH Yes ZIKV prM/E
SAM VRC_5283 GSK-NIH Yes ZIKV prM/E
SAM VRC_5288 GSK-NIH Yes ZIKV prM/E
Recombinant
subunit (non-VLP)
ZIK-80E Hawaii Biotech, Inc. No
Recombinant
subunit VLP
(non-fusion)
ZIKVLP Institut Pasteur
Shanghai, China
No
Recombinant
viral vector
NI.LV-ZIK Institut Pasteur, Paris,
France
No ZIKV prM/E None
Recombinant
viral vector
ChAdOx1-Zk Jenner Institute ZIKV prM/E None
Inactivated whole
target organism
KAKETSUKEN ZIKV Kaketsuken No ZIKV full genome TBD
Inactivated whole
target organism
NewLink Genetics No ZIKV prM/E + NS1 TBD
Recombinant
subunit VLP (fusion)
NewLink Genetics No ZIKV prM-E TBD
Live, attenuated
target organism
rZIKV/D2D30 NIAID Yes ZIKV prM/E None
Live, attenuated
target organism
rZIKV/D4D30 NIAID Yes ZIKV prM/E None
Live, attenuated
target organism
rZIKVD30 NIAID Yes ZIKV full genome None
Recombinant
viral vector
NIAID Yes None
Sf9 cells/Baculo ZIKV envelope
dimers (EnvD)
Novavax, Inc. No ZIKV E protein Matrix M adjuvant or
aluminum hydroxide
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challenge after a single intradermal immunization [38] or
after prime and boost intramuscular immunization [39].
The nucleoside-modified mRNA ZIKV vaccine (mRNA-
1325), which is being developed by Moderna, a Cambridge-
based Biotech Company [36], entered a phase 1 clinical trial
in December 2016 (NCT03014089). The mRNA candidate
developed by NIAID and GlaxoSmithKline could enter
clinical trials in late 2017.
Purified, inactivated whole virus vaccines (PIV)
The inactivation process eliminates virus replication
while maintaining the antigenicity of the structural
proteins, and thus PIV are thought to be safe during
pregnancy. PIV vaccines have been successfully licensed
for both JEV and TBEV. ZIKV PIV vaccines would most
likely be less costly than nucleic acid vaccines. However,
it is plausible that PIVs could require multiple doses in
the primary schedule, adjuvants to enhance immunogenicity,
and boosters to sustain protective immunity. ZIKV PIV de-
rived from the Puerto Rico strain PRV ABC59 or from
the MR 766 strain, produced in Vero cells, and inacti-
vated with formalin, were tested in either Balb/c mice,
rhesus monkeys, AG 129 mice, or New Zealand white
rabbits and showed good induction of ZIKV-specific
neutralizing antibodies [15, 16, 40]. Further, a ZIKV
PIV candidate with an alum adjuvant is being evaluated
in several phase 1 trials (NCT03008122, NCT02952833,
NCT02963909, NCT02937233). The results of three
phase 1 placebo-controlled, double-blind trials in
healthy adults of ZIKV PIV with aluminum hydroxide
adjuvant were recently published [41], showing only
mild to moderate adverse events. By day 57, 92% of vac-
cine recipients had seroconverted (microneutralization
titer ≥ 1:10), with peak geometric mean titres seen at day
43 and exceeding protective thresholds seen in animal
studies. NIAID’s Vaccine Research Center will test a ZIKV
Table 2 WHO – Pipeline Zika virus (ZIKV) vaccines (in preclinical development) (last updated January 2017) January 2017)
(Continued)
Platform Candidate
vaccine name
Developer/Collaborators Replicating virus
(Yes/No)
Antigen Adjuvant
nanoDNA/ZIKA-LAMP
chimera construct
LAMP-ZIKA
nanoDNA
Pharos Biologicals No ZIKV prM/E
Recombinant
subunit (non-VLP)
ZIKA recombinant Protein Sciences/Sinergium
Biotech/Lab Liomont
No ZIKV E protein Aluminum based
Peptide Replikins Zika
Vaccine and Bocker
Replikins Ltd. No Synthetic Peptides None
Recombinant
viral vector
Chimerivax-Zika Sanofi Pasteur ZIKV prM/E + NS1 None
Recombinant
viral vector
SCV-CHIKV+ZIKV
+YF
Sementis Ltd. No ZIKV, yellow fever, and
CHIKV surface antigens
None
Recombinant
viral vector
SCV-CHIKV+ZIKV Sementis Ltd. No ZIKV and CHIKV surface
antigens
None
Recombinant
viral vector
SCV-ZIKV Sementis Ltd. No ZIKV surface antigens None
Inactivated whole
target organism
Takeda No ZIKV full genome Alum
Subunit Tours University No
VLP HBV-Zika
Prime-boost U1187 INSERM
(CYROI, La Reunion)
Live attenuated
+ ZIKV exosome
Inactivated whole
target organism
Valneva No ZIKV full genome Aluminum hydroxide
Recombinant viral vector VXA-Zikavax Vaxart ZIKV prM/E
VLP VBI-2501A VBI Vaccines No ZIKV E + NS1
DNA WRAIR/BIDMC/Harvard No ZIKV prM/E
Recombinant viral vector WRAIR/BIDMC/Harvard ZIKV prM/E
BIDMC Beth Israel Deaconess Medical Center, BIKEN Research Foundation for Microbial Diseases of Osaka University, CDC Centers for Disease Control and
Prevention, CHIKV Chikungunya virus, GSK GlaxoSmithKline, LAMP loop-mediated isothermal amplification, NIH National Institutes of Health, NIAID National Institute
of Allergy and Infectious Diseases, SAM self-amplifying mRNA, SCV Sementis Copenhagen vector, VLP virus-like particles, WRAIR Walter Reed Army Institute of
Research, YF Yellow fever, ZIKV Zika virus
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PIV as a boost to its DNA Zika vaccine candidate. Bharat
and Takeda are also developing a PIV against ZIKV.
Viral-vectored vaccine candidates
Viral-vectored vaccines share the same ease of pro-
duction and stability with DNA plasmid vaccines and
may therefore be easily scalable in epidemic situa-
tions. Viral-vectored vaccines induce both innate and
adaptive immune responses in mammalian hosts [42].
Adenoviral vectors have been used to deliver ZIKV
prM-E [40], and were shown to have higher neutral-
izing antibody titers and T-cell immunity than PIV,
DNA, and protein subunit vaccines [15]. Neverthe-
less, limitations for adenovirus vaccines include their
ability to induce toxic inflammatory responses and
the potential for pre-existing immunity to naturally
occurring human adenoviruses resulting in acceler-
ated clearance and dampened immunogenicity [42].
Reactogenicity has been circumvented by the deletion
of genes required for replication, which also allows
for larger inserts [42]. Non-human primate adenovi-
ruses as vaccine vectors can bypass pre-existing im-
munity to human adenoviruses. Adenovirus-vectored
and chimpanzee adenovirus-vectored vaccines for
ZIKV are still in pre-clinical development.
The core technology of the measles vector plat-
form developed at the Institut Pasteur in Paris and
now licensed to Themis Bioscience was successfully
tested in a phase 1 trial for chikungunya virus [43].
The live recombinant measles virus-based chikun-
gunya vaccine had good immunogenicity, even in the
presence of anti-vector immunity, was safe, and had
a generally acceptable tolerability profile, making this
the first promising measles virus-based candidate
vaccine for use in humans. With regards to ZIKV,
the measles vaccine-ZIKV chimeric virus recently en-
tered a phase 1 clinical trial (NCT02996890).
Subunit protein/virus-like particles (VLPs)
Subunit protein vaccines are attractive as a platform
due to their potential for safe use in all populations,
including pregnant women, depending on adjuvants.
Subunit protein vaccines are produced by transfect-
ing a plasmid encoding a gene sequence of interest
into bacteria, yeast, or insect cells and utilizing the
machinery within those cells to produce the protein
from the gene sequence. Similar to the PIV approach,
a disadvantage to subunit protein vaccines is that
they are generally less immunogenic than live
vaccines and therefore require multiple doses and
adjuvants to achieve protective immunity. The advan-
tage of VLPs is that the antigens are presented in
their native conformation without the need for a
replicating virus. Subunit protein and VLP ZIKV vac-
cines have not yet entered clinical evaluation.
Live attenuated vaccines including recombinant
heterologous flavivirus-vectored vaccines
Live attenuated vaccines are usually a favored vaccine
technology because of their ability to induce durable
and effective adaptive immunity at relatively low
production costs. Live vaccines mimic natural viral
infections and thus induce a strong antibody and cell-
mediated immunity. However, live attenuated vaccines
induce transient low-grade viremia. As CZS is
thought to occur even in asymptomatically infected
pregnant women with low grade viremia [27], repli-
cating live vaccines need to be carefully evaluated for
their safety prior to their administration to women of
reproductive age, some of whom may be inadvertently
pregnant. However, similar to the approach to con-
genital rubella syndrome [44, 45], live attenuated Zika
vaccines may play a significant role in endemic trans-
mission use, for example, by their incorporation to
childhood vaccination programs in countries with
ZIKV transmission. As ZIKV is a neurotropic virus,
neurovirulence and reproductive toxicology testing are
critical early steps in the development of live attenu-
ated vaccines prior to human studies. Demonstration
of mosquito non-competence is also required.
Live attenuated replication-competent vaccines are
available for recombinant (or chimeric) flaviviruses.
The principle of chimerization is to insert target an-
tigens (for example, prM and E) into a back-bone
vector. Sanofi-Pasteur developed a recombinant ZIKV
vaccine based on the yellow fever virus 17D back-
bone, which has been used to develop and license
live attenuated recombinant DENV and JEV vaccines
[46]. NIH/NIAID is also using recombinant DNA
technology to design recombinant ZIKV/DENV vi-
ruses, a strategy employed in the creation of the
DENV-2 component of TV003, rDEN2/4Δ30 [47].
For the ZIKV candidate vaccine, the prM and E cod-
ing sequences of ZIKV are being evaluated, replacing
those of DENV-2 or DENV-4. Combining the NIH
tetravalent DENV vaccine with the recombinant
ZIKV/DENV component may provide a combination
DENV-ZIKV vaccine, which could be useful for pop-
ulations living in regions endemic for both.
WHO’s target product profile for a ZIKV vaccine
Non-replicating platforms with no documented safety
concerns for use during pregnancy would be the pre-
ferred vaccine platform for a ZIKV vaccine for emer-
gency use where women of reproductive age are the
primary target, ideally with a single dose primary
series [6]. Vaccines based on replication-competent
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platforms are likely to have profiles more suitable for
routine/endemic transmission use. As there is a the-
oretical risk that live, attenuated, or replication-
competent viral vaccines given to pregnant women
may be capable of crossing the placenta and infecting
the fetus [48], live vaccines are generally not recom-
mended for use during pregnancy. However, live at-
tenuated vaccines have been given to women of
child-bearing age (MMR, yellow fever, polio) in situa-
tions of increased risk of exposure, and inadvertent
vaccination of pregnant women does occur in mass
vaccination campaigns. To date, there is no evidence
of increased adverse pregnancy outcomes due to
immunization with a live attenuated vaccine [49].
However, the safety assessment and regulatory re-
quirements for live attenuated/replicating-competent
ZIKV vaccines are likely to require additional data
compared to non-replicating vaccine platforms. Non-
replicating vaccine platforms that either do not use
any adjuvant or use a well-characterized adjuvant in
currently licensed vaccines, such as aluminum salts
(e.g., alum), would be preferable. However, the use of
other adjuvants may be justifiable if accompanied
with superior performance and delivery aspects (e.g.,
reduced number of doses).
Zika therapeutics
Therapeutics against ZIKV need to be developed in
parallel to vaccines and may have a specific role in
reducing the burden of Zika infection and disease in
the populations most at risk of serious outcomes.
Drugs could rationally be used for prophylaxis or
post-exposure prophylaxis to prevent or mitigate the
severity of CZS, and may have particular value when
low endemicity does not justify widespread
immunization. Aborting ongoing ZIKV shedding in
seminal fluids may be another indication. Antivirals
are the cornerstone of management of chronic hu-
man viral infections like HIV, hepatitis B, and hepa-
titis C. There are also precedents for therapies to
manage viral infection in pregnant women and their
fetus such as post-exposure prophylaxis with immune
immunoglobulins in susceptible women to protect
the mother and fetus from infection with varicella.
Any new drugs for ZIKV would be used as an ad-
junct to the standard of care for non-pregnant and
pregnant persons, and may be indicated before vac-
cines become widely available or in addition to vac-
cine programs.
Three plausible clinical indications for application of a
medicinal prophylactic/therapeutic against ZIKV are (1)
to offer prophylaxis or early post-exposure prophylaxis,
(2) to accelerate viral clearance, and (3) to reduce
disease severity (Box 1).
Human immune globulin and anti-ZIKV monoclonal
antibodies (mAb) for prophylaxis or treatment
Human immune globulins are used clinically against
some viral infections in pregnant women. For measles,
the primary purpose is to attenuate disease in the preg-
nant woman and prevent perinatal transmission to the
newborn. For varicella, the purpose is to prevent or
attenuate disease in the pregnant woman and prevent
congenital infection [50]. However, the incubation time
of varicella is 2–3 weeks, far longer than for ZIKV (3–
10 days), and therefore the critical time to treat is
shorter for ZIKV. Plausibly, human immune globulin (or
hyperimmune globulin) from ZIKV-immune donors, or
human mAbs, could be used for prophylaxis or therapy.
mAbs are promising because they can be precisely de-
fined and their production controlled and scaled up.
Blood from a ZIKV-immune donor and a human B-cell
immortalization technique was used to identify human
mAbs that bound ZIKV antigens (NS1 and E proteins)
[51]. An EDIII-specific antibody, ZKA190, protected
mice from lethal ZIKV infection, illustrating the poten-
tial for antibody-based therapy. Another mAb, ZIKV-
117, was identified as broadly neutralizing of ZIKV
infection in vitro [52]. Epitope mapping studies have re-
vealed that ZIKV-117 recognized a unique quaternary
epitope on the E protein dimer-dimer interface. Treat-
ment of Zika-infected pregnant and non-pregnant mice
with ZIKV-117 markedly reduced tissue pathology, pla-
cental and fetal infection, and mortality. A bispecific
mAb has also been developed that could address con-
cerns about the emergence of anti-viral resistance to
monospecific mAbs [53]. Collectively, these data demon-
strate the feasibility of developing mAbs as therapeutic
and/or prophylactic candidates.
Small molecule antivirals for prophylaxis or treatment
Multiple studies have demonstrated the anti-ZIKV activ-
ity of several Food and Drug Administration (FDA)-ap-
proved drugs or drug candidates being clinically tested
for other indications [54–59]. For example, the anti-
HCV prodrug Sofosbuvir has anti-Zika virus activity in
vitro [54]; however, repurposing this compound is prob-
lematic because its hydrolysis is highly specific to the
liver. Niclosamide, a category B anthelmintic drug,
inhibited ZIKV replication at low micromolar concentra-
tions [58]. However, the poor systemic bioavailability of
niclosamide is a hurdle to further clinical development
against Zika. More than 20 out of 774 FDA-approved
drugs decreased ZIKV infection in an in vitro screening
assay [54]. Selected compounds were further validated for
inhibition of ZIKV infection in human cervical, placental,
and neural stem cell lines, as well as in primary human
amnion cells. Established anti-flaviviral drugs (e.g., borte-
zomib and mycophenolic acid) and others with no
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Box 1: Clinical indications for application of a prophylactic/therapeutic against Zika
INDICATION 1. PROPHYLAXIS OR EARLY POST-EXPOSURE PROPHYLAXIS.
(1) To prevent maternal infection and fetal disease:
The objective is to prevent, or diminish, Zika virus (ZIKV) infection and disease in pregnant women, or women trying to become
pregnant, and thus eliminate or substantially reduce the probability of intrauterine infection or transmission in the perinatal or
postnatal period.
 Examples of this approach for Zika. Prophylaxis for a pregnant woman living in a setting where there is epidemic Zika
transmission, or a pregnant traveler spending time in a Zika-affected location. Post-exposure prophylaxis might be considered
where there is strong suspicion that a pregnant woman has been exposed to Zika because of epidemiological circumstances (e.g.,
lives in an endemic area and resides in a household where recent Zika cases have been diagnosed)
 Challenges. The risk/benefit of using prophylactic agents (small molecule drugs or immune globulin) must be balanced against the
probability of the mother and fetus being infected and of that infection harming the fetus
 Examples of this approach for other infectious diseases. Varicella virus (chickenpox) infection during pregnancy may result in
congenital varicella, which is usually benign and self-limiting, but can occasionally produce a characteristically severe pattern of
abnormalities known as ‘congenital varicella syndrome’. Zoster immunoglobulin (a preparation of human Ig containing
anti-varicella antibodies) is indicated for all pregnant women who have significant exposure to Varicella Zoster virus infection
(defined as ‘living in the same household as a person with active chickenpox or herpes zoster or face-to-face contact with a person
with chickenpox or uncovered zoster for at least 5 minutes’), who have no history of chickenpox and who are seronegative.
(2) To prevent Guillain–Barre Syndrome or other ZIKV infection-related neurological complications.
Prophylaxis throughout the duration of exposure (e.g., travel to a Zika endemic area).
Early post-exposure prophylaxis after known exposure to a Zika case (e.g., sexual exposure, nosocomial exposure such as needle stick
injury, living in same household of a current Zika case).
INDICATION 2. THERAPY TO ACCELERATE RESOLUTION OF INFECTION
 Examples of this approach for Zika. A pregnant woman, who lives in a setting where ZIKV is known to circulate, presents
to a clinic with clinical signs and symptoms that could represent ZIKV infection. Out of an abundance of caution, empiric
treatment commences before the results of laboratory tests are known (if such tests are available). The purpose of treatment
is to accelerate clearance of virus infection from the maternal tissues and mitigate the likelihood of intrauterine or peri- or
postnatal virus infection. A second example of treatment is for neonates who have acquired ZIKV from intrauterine
exposure or perinatally.
 Challenges. As for prophylaxis, the use of a therapeutic agent must be balanced by the safety and cost profile of the drug
and the likelihood that treatment will deliver clinical benefits to the fetus, i.e., prevent or modify intrauterine infection.
For many Zika cases, viremia is already in rapid decline, or even undetectable by the time the patient presents to
healthcare providers. An additional delay is created if treatment is guided by laboratory diagnostics rather than an
empiric approach.
 Examples of this approach for other infectious diseases. There are no examples for acute viral infections, but in the setting
of chronic infections such as HIV, it is well accepted that vertical transmission is RNA copy number-dependent, with higher
rates occurring with increasing viral loads present in the mother. Treatment of pregnant women has been demonstrated to
drastically reduce the incidence of vertical transmission in women undergoing treatment with a combination of antiretroviral
compounds [82].
INDICATION 3. DISEASE MODIFICATION FOR EXISTING CONGENITAL INFECTION.
The objective is the treatment of existing intrauterine fetal infection by eradication of virus and thus reduce the severity of congenital
Zika syndrome.
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previously known antiviral activity (e.g., daptomycin) were
identified as inhibitors of ZIKV infection. These results
offer the possibility of a repurposed drug being used for
Zika therapeutic or prophylactic indications.
Newly discovered candidate anti-virals include a synthetic
peptide derived from the stem region of the ZIKV envelope
protein, designated Z2, which potently inhibits infection of
ZIKV and other flaviviruses in vitro [60]. Z2 is able to pene-
trate the placental barrier to enter fetal tissues and prevent
vertical transmission of ZIKV in pregnant C57BL/6 mice
[60]. Another molecule, galidesivir, is an adenosine
analogue active in cell culture against a wide-range of RNA
viruses [61]. Galidesivir treatment of ZIKV-infected mice
significantly improved survival even when treatment was
initiated 5 days after infection [62]. However, potential hur-
dles for galidesivir development is the requirement for an
oral formulation (galidesivir requires parenteral administra-
tion). Ribavirin, another broad-spectrum but teratogenic
antiviral, did not improve outcomes from ZIKV infection in
the same model (Cristina Cassetti; personal communica-
tion). A summary of compounds found to have Zika anti-
viral properties in vitro (Table 3) and of some of the
repurposed drugs reported to have anti-Zika activities are
provided herein (Table 4).
Challenges for clinical evaluation of Zika vaccines
and therapeutics
Various challenges may delay or hinder the successful licen-
sure of Zika vaccines or therapeutics, as described below.
Selection of the most suitable clinical endpoint
In June 2017, WHO convened a meeting to elaborate on
clinical endpoints for ZIKV vaccine efficacy trials [10]. Al-
though preventing CZS is the outcome of greatest interest
for public health, the large sample sizes required, the focus
on women only, the heterogeneity of clinical manifesta-
tions of CZS, and ethical considerations render CZS as
the primary endpoint unfeasible. A possible endpoint for
Table 3 List of potential compounds for repurposing with anti-Zika activity, extracted from [19, 83]
Drug group Drug name Description
Nucleoside analogs Sofosbuvir, MK-608 • Inhibit Zika virus (ZIKV) replication in cellular assays
• Efficacious in animal models
2CMC, Ribavirin,
Favipiravir, T1105
• Showed antiviral activity in cell culture
BCX4430, GS5734 • Reduced mortality in ZIKV-infected mice
• Currently in phase I and II clinical trials
Peptidomimetic agents CN-716 • Inhibit ZIKV protease in vitro, but only weakly inhibit viral replication
• Due to safety reasons, may not translate as therapeutic option for pregnant women,
but could be applied to other infected individuals
Adenosine analog NITD008 • Showed potent anti-ZIKV activity
• Could serve as a reference inhibitor for future drug screen and discovery
Cyclin-dependent
kinase inhibitor
PHA-690509 • Showed inhibition of ZIKV replication of all three strains
Antimalaria Chloroquine • Reduces virus production, the number of infected cells, and cell death promoted by
ZIKV infection without any cytotoxic effect
• Promising candidate for ZIKV clinical trials
• Can be safely administered to pregnant women since it is clinically approved
Anthelmintic Bithionol • Propagate by activating host caspases and inducing programmed cell death
Epigallocatechin gallate • Natural compound found in food items, particularly green tea
• It inhibits ZIKV entry into host cell
Interferon-inducible
transmembrane proteins
• Inhibit the replication of a number of pathogenic viruses
 Examples of this approach for Zika. A pregnant woman has amniocentesis performed because of concerns about recent
exposure to ZIKV. The amniocentesis fluid is RT-PCR positive for ZIKV. Treatment is commenced to eradicate virus from
the fetal tissues.
 Challenges. This indication is unlikely to be the sole basis for drug development. Clinical trials to test for improvements in fetal
outcome would be very long in duration and likely prohibitively expensive to perform. The extent of viremia in the pregnant
woman before commencement of treatment may already have led to significant pathology of the fetus.
 Examples of this approach for other infectious diseases. Unfortunately, there is no evidence that the outcome of an established
congenital viral infection (e.g., with cytomegalovirus or varicella) can me modified by small molecule drug or immunoglobulin treatment.
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clinical trials could be ZIKV infection (whether symptom-
atic or not), which would require a smaller sample size
compared to a clinical endpoint. However, detecting
asymptomatic ZIKV infections (as measured by serocon-
version or sampling for virological detection) poses several
challenges, including the requirement of very frequent
blood, urine, and possibly semen collection so as not to
miss the acute infection and achieve virological diagnosis
[63]. Vaccination may also interfere with serological test-
ing, e.g., it may render it difficult to discriminate between
vaccine response and natural infection. A challenge with
using clinical disease as the primary endpoint is that ZIKV
illness is often associated with mild and non-specific
symptoms, which raises challenges for case detection. A
standardized clinical case definition is essential to facilitate
the comparison and combining of information from dif-
ferent studies. A working case definition of virologically
confirmed Zika illness has been provided by the Pan
American Health Organization [64].
The consensus at the WHO technical consultation in
June 2017 was to select virologically confirmed clinical ill-
ness as the primary endpoint, and to additionally study a
subset to explore the protection against infection or reduc-
tion in viremia. The underlying assumption is that reduc-
tion in ZIKV disease incidence is associated with either
sterilizing immunity or a reduction in ZIKV viremia, which
in turn will reduce or prevent subsequent development of
complications in pregnant and non-pregnant individuals.
Inclusion of pregnant women in trial design and safety
considerations
Although pregnant women would not be the primary
target population for efficacy trials based upon the above
rationale, pregnant women remain a priority population
for ZIKV vaccine use in areas experiencing ongoing
transmission and in future outbreaks. Thus, the Ethics
Working Group on ZIKV Research and Pregnancy [65]
recommended the collection of data specific to safety
and immunogenicity in pregnancy for all ZIKV vaccine
candidates to which pregnant women may be exposed
and ensuring that pregnant women have fair access to
participate in ZIKV vaccine trials that offer a favorable
ratio of risks to potential benefits. Clinical development
plans should therefore include systematic collection of
relevant indicators and outcomes of safety and efficacy
for pregnant women. Although certainly a complex chal-
lenge, a concerted and proactive effort is required to ad-
dress the needs of pregnant women and their offspring
early and across the ZIKV vaccine R&D pathway.
Sample size and trial site selections
Generating clinical efficacy data in a reasonable sample
size and an acceptable timeframe and cost is challenging
at a time when global Zika incidence has declined to low
levels. Areas with recent active ZIKV transmission may
not be the best sites for clinical trials. Given that estimates
of ZIKV seroprevalence are as high as 70% in some areas
that experienced an outbreak, the proportion of suscep-
tible individuals in such populations will be low, with a
subsequent incidence too low to sustain an efficacy trial.
Therefore, the WHO technical consultation in June 2017
proposed the projection of future evolution of the ZIKV
epidemic based on the presence and vectorial capacity of
Aedes mosquitoes [66, 67], travel patterns [68–70], and
risk mapping and modeling [71–74] to predict the move-
ment of Zika [75, 76]; various mathematical modeling
groups are working to this end. A multi-site approach for
vaccine trials will be needed to increase the chance of in-
cluding populations with a high incidence of disease, as
well as providing an opportunity to evaluate vaccine effi-
cacy across different populations.
Immune correlates
An immune correlate of protection is an immune
response marker that is statistically associated with pro-
tection from disease or infection and may be either
mechanistic (causally related to outcome) or non-
mechanistic/surrogate (statistically related to outcome).
Given the global decline in cases, it is unclear whether
Table 4 High throughput screening for potential compounds with anti-Zika activity (drug repurposing)
Study No. of drugs
screened
Compounds identified with anti-Zika activity Remarks
Barrows et al. [54] 774 FDA-approved
agents
Clofazimine, Digoxin, Gemcitabine, Ivermectin,
Mefloquine, Mercaptopurine hydrate, Mycophenolic
acid, Fingolimod, Mycophenolate mofetil, Dactinomycin,
Bortezomib, Methoxsalen (Xanthotoxin), Azathioprine,
Thioguanine, Auranofin, Sertraline, Pyrimethamine,
Daptomycin, Palonosetron, Deferasirox, Micafungin,
Sorafenib tosylate, Cyclosporine A, Mebendazole
• Mycophenolic acid (MPA), Ivermectin,
Daptomycin, Mefloquine, Palonosetron
identified as having higher potency
• Daptomycin, Mefloquine, and Palonosetron are
pregnancy category B drugs
Xu et al. [58] 6000 compounds,
> 2000
FDA-approved agents
Niclosamide, Emricasan, 10 structurally unrelated
inhibitors of CDK
• Emricasan is an inhibitor of caspase-3 activity
but uncertain if a capase-3 inhibitor with
anti-inflammatory properties impacts
development of unborn fetus
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large scale efficacy trials are viable given the current in-
cidence of ZIKV transmission. If clinical efficacy trials
are not feasible, immune correlates/surrogates derived
from passive protection studies in animals, natural his-
tory studies, and controlled human challenge study re-
sults may possibly represent acceptable endpoint data
for initial emergency use authorization and eventual
licensure. ‘Accelerated approval’ is based on the demon-
stration of a surrogate of protection though well-
controlled clinical studies that are reasonably likely to
predict clinical benefit. The US FDA ‘animal rule’ is
based on the demonstration of an immune marker of
protection in animal models that will reasonably likely
predict clinical benefits in humans. Both accelerated ap-
proval and animal rule approaches require post-
licensure studies to verify clinical benefit and safety.
Controlled human infection models are a promising av-
enue to explore immune correlates in humans, however,
they are associated with complex ethical considerations.
The feasibility of establishing immune correlates or sur-
rogates is now a priority.
Assay optimization and standardization
A comprehensive review of ZIKV diagnostics was recently
performed [77] and shortcomings highlighted [63]. In the
context of a highly epidemic disease with an apparent short
duration of detectable viremia and relatively infrequent inci-
dence of clinical disease, reliable case ascertainment in effi-
cacy trials is critical. However, the short and relatively low
level viremia is difficult to detect, and the serological assays
lack specificity because of cross-reactivity between other co-
circulating flaviviruses and flavivirus vaccines [78]. Frequent
sampling over time and sampling of various bodily fluids
(whole blood, serum, urine), as well as the combination of
various diagnostic assays will be necessary to increase the
diagnostic yield. For the comparability of clinical trial re-
sults, it is crucial to standardize diagnostic assays used
and immunological reference reagents should be available.
The plaque reduction neutralization test is still considered
to be the laboratory standard against which other neutral-
izing antibody assays should be compared. A guideline on
plaque reduction neutralization test standardization can
be found on the specific WHO website [79].
Interaction between DENV and ZIKV
Given the widespread endemicity of DENV in the areas
most affected by the current ZIKV outbreak, and the fact
that short- or long-term immunological interaction be-
tween DENV and ZIKV cannot currently be excluded, trials
would ideally need to take baseline blood samples for all
subjects to ascertain prior DENV exposure in order to
study the impact of prior immunity to DENV on vaccine
performance and safety. For DENV vaccines, WHO recom-
mends that subjects are followed-up for safety and efficacy
for at least 3–5 years from the time of completion of pri-
mary vaccination due to the concern of immune enhance-
ment [80]; however, given the lack of data supporting a
clinical significant interaction between DENV and ZIKV
[26–28], such a formal recommendation has not yet been
made for Zika vaccine development. Nevertheless, a longer
follow-up period to monitor safety could be considered.
Establishing a transparent framework for selecting vaccines
Given the global decline in ZIKV incidence and the po-
tential bottleneck in identifying suitable trial sites, a pro-
posal was made during the June 2017 WHO technical
consultation to establish a transparent framework for
prioritizing vaccines to be evaluated in phase 2b/3 trials.
Selection criteria would depend on the desired attri-
butes, including compliance with the target product pro-
file, pre-clinical evidence of complete or near-complete
prevention or reduction of viremia, safety during preg-
nancy, and scalability of the product.
Donor and industry fatigue
Major vaccine producers, government-funded insti-
tutions, academics, and small to mid-size research
enterprises responded promptly to the Zika out-
break, setting aside other activities to focus on rap-
idly developing vaccines and therapeutics against
Zika, supported by government and philanthropic
funding agencies. However, with the rapid decline in
cases, the unpredictability of future outbreaks, and
the still poorly defined use scenarios, the commer-
cial market has become questionable. The prospect
of a licensed Zika vaccine is at stake unless govern-
ments and other donors sustain the level of support
to advance development. Current models for stimu-
lating epidemic product development are failing. The
Coalition for Epidemic Preparedness Innovations
(CEPI) is a new alliance between governments, in-
dustry, academia, philanthropy, intergovernmental
institutions (such as WHO), and civil society, and
was founded to finance and coordinate the develop-
ment of new vaccines to prevent and contain infec-
tious disease epidemics [81]. Zika is not yet on the
priority list for CEPI, but as donor and industry fa-
tigue may increase, CEPI, or such other mecha-
nisms, will be needed to ensure that, out of the
many Zika vaccine candidates, at least one will make
it to the finish line.
Conclusion
At least 45 Zika vaccine candidates have been or are in
development, some of them already in phase 2 clinical
trials. Multiple vaccine platforms have shown robust
protection against ZIKV challenge in animal models.
However, unique challenges will need to be addressed in
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the clinical development and regulatory pathways of a
ZIKV vaccine that may hinder the development, licen-
sure, and WHO-prequalification of high-quality, safe,
and effective ZIKV vaccines. Implementing phase 3 effi-
cacy trials will be difficult given the challenges of the
spatial and temporal heterogeneity of ZIKV transmis-
sion, the unpredictability of the ZIKV epidemics, the
broad spectrum of clinical manifestations making a sin-
gle definite endpoint difficult, the lack of sensitive and
specific diagnostic assays, and the need for inclusion of
vulnerable target populations. In addition to a vaccine,
drugs for primary prophylaxis, post-exposure prophylaxis,
or treatment should also be developed in order to prevent
or mitigate the severity of CZS. The global research and
public health community should prioritize the develop-
ment of ZIKV vaccines and therapeutics that will be ac-
ceptable for use by women of reproductive age, and ensure
availability and affordability for use in countries where
ZIKV is circulating. To this end, WHO is working towards
a roadmap for Zika vaccine and product development.
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